47.[20221006]Desensitization in Crossmatch-positive Kidney Transplant …
페이지 정보
작성자 신호식 작성일23-02-03 13:36 조회457회 댓글0건관련링크
-
https://youtu.be/7IVSd00Onr4
464회 연결
https://youtu.be/7IVSd00Onr4
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review Transplantation
. 2023 Feb 1;107(2):351-360. doi: 10.1097/TP.0000000000004279. Epub 2022 Aug 5.
Desensitization in Crossmatch-positive Kidney Transplant Candidates
Johan Noble 1 2, Thomas Jouve 1 2, Paolo Malvezzi 1, Lionel Rostaing 1 2 3
Affiliations expand
PMID: 35939390 DOI: 10.1097/TP.0000000000004279
Abstract
Access to kidney transplantation is limited by HLA-specific sensitization. Desensitization strategies enable crossmatch-positive kidney transplantation. In this review, we describe clinical experience gained over the last 20 y using desensitization strategies before kidney transplantation and describe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, proteasome inhibition, enzymatic degradation of HLA antibodies, complement inhibition, and B cytokine interference. Although access to transplantation for highly sensitized kidney transplantation candidates has been vastly improved by desensitization strategies, it remains, however, limited by the recurrence of HLA antibodies after transplantation and the occurrence of antibody-mediated rejection.
Review Transplantation
. 2023 Feb 1;107(2):351-360. doi: 10.1097/TP.0000000000004279. Epub 2022 Aug 5.
Desensitization in Crossmatch-positive Kidney Transplant Candidates
Johan Noble 1 2, Thomas Jouve 1 2, Paolo Malvezzi 1, Lionel Rostaing 1 2 3
Affiliations expand
PMID: 35939390 DOI: 10.1097/TP.0000000000004279
Abstract
Access to kidney transplantation is limited by HLA-specific sensitization. Desensitization strategies enable crossmatch-positive kidney transplantation. In this review, we describe clinical experience gained over the last 20 y using desensitization strategies before kidney transplantation and describe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, proteasome inhibition, enzymatic degradation of HLA antibodies, complement inhibition, and B cytokine interference. Although access to transplantation for highly sensitized kidney transplantation candidates has been vastly improved by desensitization strategies, it remains, however, limited by the recurrence of HLA antibodies after transplantation and the occurrence of antibody-mediated rejection.
